Opinion|Videos|April 25, 2025

Implementation Factors Affecting Ruxolitinib Adoption in Pediatric Dermatology Practice

Alexandra Golant, MD discusses how cost considerations, insurance barriers, formulary restrictions, and effective caregiver education about proper application will significantly impact the widespread adoption of ruxolitinib cream in pediatric dermatology practice.

Episodes in this series

This news content has been independently developed and is not endorsed by the American Academy of Dermatology.

Video content above is prompted by the following:

  • Beyond efficacy and safety, what other factors—such as cost, insurance coverage, or caregiver education—will determine how widely ruxolitinib cream is adopted in pediatric dermatology, specifically in younger children?

Newsletter

Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.


Latest CME